BioCentury
ARTICLE | Clinical News

Plasma-derived Alpha-1 antitrypsin: Phase I/II data

November 24, 2014 8:00 AM UTC

The open-label, U.S. Phase I/II VCU-Alpha1RT trial in 10 adults with acute STEMI showed that a single dose of 60 mg/kg AAT given within 12 hours of hospital admission was well tolerated with no in-hos...